🩺Efferon NEO Cuts Pediatric Sepsis Mortality by Filtering Blood Toxins
A new device could save millions of kids from sepsis
TL;DR
Efferon's NEO device, the first multimodal blood purification tool for pediatric sepsis, has received a CE mark and is used in 30 countries. It filters out deadly toxins and cytokines, potentially saving millions of children annually.
Efferon's NEO device is a groundbreaking medical tool designed to combat pediatric sepsis, a leading cause of childhood mortality. The device filters blood to remove deadly toxins and cytokines, which are key to reducing organ failure rates and accelerating recovery. With a CE mark since April, it's already in use across 30 countries, and the company aims for FDA approval soon. This could be a game-changer for children suffering from sepsis, with the potential to save millions of lives annually.
Key Points
Efferon NEO is the first multimodal blood purification device for pediatric sepsis, receiving a CE mark in April 2023.
The device is used in intensive care units across 30 countries, reaching a wide patient base.
Efferon aims to file for FDA approval, expanding its reach to the US market.
The startup's technology was developed by scientists at Moscow State University and commercialized by a serial entrepreneur.
Efferon measures success by every child who gets to go home, aiming for $2 million in annualized revenue by 2026.
Why It Matters
Efferon's NEO device is a critical tool for pediatric ICU teams, offering a new way to combat sepsis. It filters out deadly toxins and cytokines, potentially saving millions of children annually. The device's multimodal approach to blood purification sets it apart, making it a must-have for any hospital treating sepsis in children.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,565 builders reading daily.